AI in Oncology - Precision Therapy & Prognosis by Chakraborty, Anirban
MIDDLE EUROPEAN SCIENTIFIC BULLETIN ISSN 2694-9970  97  




AI in Oncology - Precision Therapy & Prognosis 
 
Anirban Chakraborty 




Artificial intelligence (AI) has strong logical reasoning abilities and the ability to learn on its own, 
and it can mimic the human brain's thought process. Machine learning and other AI technologies 
have the potential to greatly enhance the existing method of anticancer medicine development. 
However, AI currently has several limits. This study investigates the evolution of artificial 
intelligence technologies in anti-cancer therapeutic research, such as deep learning and machine 
learning. At the same time, we are optimistic about AI's future. 
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1. INTRODUCTION 
The intelligence demonstrated by computers produced by humans is referred to as "artificial 
intelligence" (AI). Computer science, cybernetics, neurophysiology, psychology, and linguistics are 
all included in this large field. At the Dartmouth meeting in 1956, AI was considered to have been 
born. After decades of fast advancement [1–3], artificial neural networks, machine learning, deep 
learning, and other technologies have all been added to the notion of AI [1–3]. Deep learning, a 
subclass of AI, can extract characteristics from massive amounts of data automatically [3]. Deep 
learning can also identify information in photos that the human eye cannot [4–6]. This is critical for 
the early diagnosis of tumours using imaging data. AI may also help with cancer detection and 
therapy. AI is typically built on a multi-layer neural network structure with excellent logical 
reasoning and learning ability that may closely resemble human thought patterns [7,8]. AI, like the 
human brain, can solve issues by making the quickest and most intuitive decisions. It is not difficult 
to infer that AI may significantly improve present cancer research models. 
2. Objectives 
The following are the goals of this study: 
 Cancer Diagnosis 
 Cancer Prognosis 
 Development of Cancer Drugs 
 Cancer treatment with pinpoint accuracy 
 Cancer Treatment 
 AI-assisted chemotherapy 
 AI-assisted radiotherapy  
 AI and the discovery of anticancer drugs 
3. USAGE OF AI IN ANTI CANCER DRUGS CREATION 
AI may be used to forecast anticancer medication action or to aid in the discovery of anticancer 
drugs. Distinct malignancies and medications may have different response modes, and results from 
high-throughput screening processes often demonstrate a link between cancer cell genetic diversity 
and drug activity. Lind et al. [9] used screening data with machine learning to create a random forest 
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model. According to the mutation status of the cancer cell genome, the model may predict the action 
of anticancer medications. Wang et al. [10] created a drug sensitivity prediction model based on an 
elastic net regression machine learning algorithm. Machine learning algorithms have been shown to 
accurately predict medication sensitivity in patients with ovarian cancer [11–13], gastric cancer [14–
16], and endometrial cancer [11–13]. 
 
Fig 1 The applications of AI in tumors 
Cancer imaging, screening, and diagnosis, cancer therapy, cancer medicine, and other domains have 
the potential to be enhanced by AI. Cancer research and therapeutic treatment have the potential to 
be advanced by AI. Cancer imaging should be the most developed use of AI in the area of cancer at 
the moment. Some outstanding AI performance fits the demands of medical imaging, and the 
combination of the two may advance cancer research[17,18]. The model predicts resistance in 
patients with ovarian cancer treated with tamoxifen, gastric cancer treated with 5-FU, and 
endometrial cancer treated with paclitaxel. These individuals were all found to have a dismal 
prognosis. This research demonstrates that artificial intelligence has a high potential for forecasting 
the sensitivity of anticancer treatments. AI is also being used to combat medication resistance in 
cancer [19–21]. By learning and analysing data on big drug-resistant cancers, AI can swiftly 
comprehend how cancer cells grow resistant to cancer treatments, which may assist in improving 
medication development and drug usage (Fig. 1). 
4. Chemotherapy and AI 
In the realm of cancer treatment, AI is mainly concerned with the interaction between medications 
and patients. The key application successes of AI are chemotherapy drug usage management, 
prediction of chemotherapy drug tolerance, and chemotherapy programme optimization [22–25]. 
Combination chemotherapy has the potential to improve and speed up the process of optimising. In 
one study, the researchers successfully determined the optimal dose of zen-3694 and enzalutamide 
using "CURATE.AI" (an artificial intelligence platform developed by the National University of 
Singapore that uses deep learning and other technologies), thereby improving the efficacy and 
tolerance of the combined treatment [26]. Inhibitors of poly ADP-ribose polymerase (PARP) may be 
used to treat breast cancer cells that lack homologous recombination (HR). Gulhan et al. [27] created 
a deep learning-based screening method that can identify cancer cells with HR defects with 74% 
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accuracy and predict which patients would benefit from PARP medicines. Dorman et al. [28] created 
a machine learning model that predicts breast cancer tolerance to treatment. The research, which 
looked at the interaction between chemotherapy medications and patients' genes, was able to tell the 
difference between the effects of two chemotherapy treatments, taxol and gemcitabine. Furthermore, 
research has demonstrated that the deep learning technique outperforms the Epstein-Barr Virus-
DNA-based model in risk classification and induction chemotherapy guidance for nasopharyngeal 
cancer [29]. This suggests that the deep learning method's directing function may be employed as a 
possible signal for predicting single induction chemotherapy for advanced nasopharyngeal cancer 
[30]. 
5. Radiotherapy and artificial intelligence 
The use of AI technology in cancer radiation is more particular. AI can assist radiologists in mapping 
out target regions and automatically planning radiation therapy regimens [31–33]. Lin et al. [34] used 
a three-dimensional convolutional neural network (3D CNN) to identify nasopharyngeal cancer with 
79 percent accuracy, which is comparable to radiation professionals.Cha et al. [35] integrated deep 
learning technology with radiomics (the extraction of picture attributes from radiographic images) to 
create a prediction model that can assess the response to bladder cancer therapy. Babier et al. [36] 
created deep learning-based automation software that decreased the time it needed to schedule 
radiation treatment to only a few hours. The AI software's treatment plan is equivalent to patients' 
traditional treatment plans, and the time is considerably reduced (Fig. 2). 
6. Immunotherapy and artificial intelligence 
In the context of cancer immunotherapy, AI primarily focuses on assessing treatment efficacy and 
assisting clinicians in making treatment plan adjustments [37–40]. Sun et al. [41] created a machine 
learning-based AI platform to effectively anticipate the therapeutic impact of programmed cell death 
protein 1 (PD-1) inhibitors. This platform is capable of assessing the efficacy of immunotherapy in 
patients with advanced solid malignancies who are responsive to PD-1 inhibitors. Bulik-Sullivan et 
al. [42] created a machine learning system based on a human leukocyte antigen (HLA) mass 
spectrometry database that may enhance cancer neoantigen detection and the effectiveness of cancer 
immunotherapy. The use of AI in cancer radiation primarily comprises the identification of cancer 
target areas, the identification of organs at risk, and the automated creation of treatment plans. The 
AI system can perform intelligent delineation of radiative pictures without the need for human 
registration, interpolation, or other processes. Furthermore, AI can forecast three-dimensional dosage 
distributions based on mapped organs and target locations, allowing for more tailored treatments to 
be automated. 
 
Fig 2 Automatic delineation of tumors and organs at risk 
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7. AI helps to decrease cancer overtreatment. 
Hu et al. [43] created an algorithm that can evaluate digital pictures of a woman's cervix and properly 
identify precancerous lesions that need to be treated, reducing patient overtreatment. Bahl et al. [44] 
created a machine learning technique that helps prevent overtreatment of breast cancer lesions. The 
technology can predict which high-risk breast lesions are likely to develop into cancer, allowing 
clinicians to make better treatment choices and avoid needless surgery. 
8. Artificial intelligence and clinical decision support systems 
Deep learning technology improves the intelligence of cancer treatment decisions. AI can determine 
the best treatment plan for clinicians by learning from large clinical datasets of cancer patients 
[33,45–49].Printz et al. [50] created a deep learning-based Clinical Decision Support System (CDSS) 
that can extract and analyse a huge quantity of clinical data from medical records and produce cancer 
therapy alternatives. The study illustrates the significance of AI technology in assisting doctors in 
improving cancer treatment strategies for patients. 
9. Machine learning and deep learning in the creation of anticancer drugs 
Machine learning algorithms may be trained on high-throughput screening data to create models that 
predict how cancer cell lines and patients will respond to novel medications or treatment 
combinations [51–53]. Machine learning is being used by scientists to design and build reverse 
synthesis routes for compounds, which is speeding up drug discovery. The whole process of 
developing a new medicine generates a large amount of data. Machine learning provides an excellent 
chance to analyse chemical data and provide insights that can aid in drug development [54–56]. 
Machine learning may assist us in processing data accumulated over years, or even decades, in a 
relatively short period of time [57]. Furthermore, technology will allow us to make better-informed 
judgments that would previously have needed prediction and testing [58–60]. Deep learning is a one-
of-a-kind machine learning technique that has excelled in a variety of fields, including drug 
discovery [61–63]. These models have distinct properties that may make them more appropriate for 
complicated tasks such as predicting drug responses based on biological and chemical data. 
However, the use of deep learning in drug response prediction has just recently been investigated. 
Deep learning has lately been used to produce ground-breaking advancements in how computers 
extract information from photos. Deep learning techniques based on large-scale data sets have 
resulted in intriguing new medication reuse potential. One such piece of research is that of Kadurin et 
al. [64]. To construct a deep learning model, they applied the antagonistic autoencoder to the entire 
dose-response data recorded in the NCI-60 cell line. 
10. Conclusion 
AI has made significant advances in the creation and therapy of anticancer drugs [65–67]. Humans 
are constrained by their own degrees of knowledge, making it difficult to devise the best therapy. 
According to this viewpoint, if physicians choose the wrong therapy, patients may lose out on critical 
treatment chances and may even have their condition worsen. It has the potential to provide critical 
insights and information that human identification cannot, as well as to personalise therapy for each 
cancer patient [68–70].AI might hasten the identification of novel materials, perhaps hastening the 
creation of anticancer treatments. AI is expected to be a significant driving factor in human cancer 
research and therapy in the future. We think that artificial intelligence will have a significant impact 
on medical technologies in the future. 
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